American Telemedicine Association CEO abruptly steps down

Jonathan Linkous has resigned as CEO of the American Telemedicine Association (ATA), the group announced on Aug. 7, after leading the organization since it was founded in 1993.

“Jon was integral in the formation of the ATA and the telehealth industry,” Peter Yellowlees, MD, MBBS, ATA’s current board president, said in a statement. “We thank Jon for his many years of service and his significant contributions to ATA and the industry he helped create.”

Taking over the role on an interim basis will be Sabrina Smith, DHA, the group’s COO since January. A search for a permanent replacement is now underway, according to the ATA.

The sudden departure of Linkous brought up questions about whether he left voluntarily. Other groups in the health technology space, like the The Healthcare Information and Management Systems Society (HIMSS) have announced changes in leadership many months in advance. Yellowlees told POLITICO that Linkous “had a few life changes, I think,” but added the board thought he had done a “very, very good job overall” as the group’s leader.

During Linkous’s 24 years in charge, the group had grown to nearly 10,000 members. It wasn’t, however, seen as the main representative of the growing telehealth field.

“You would expect them to have a bigger voice in the Washington policy arena,” Neal Neuberger, a former executive director of HIMSS’s Institute for eHealth Policy who has consulted for the ATA since 2016, said to POLITICO. “They just didn’t.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.